Kura Oncology, Inc.
Kura Oncology is a biopharmaceutical company that develops and commercializes precision medicines for cancer and other diseases. Its products and pipeline include small-molecule menin inhibitors and farnesyl transferase inhibitors. Its first commercial product, KOMZIFTI (ziftomenib), is approved in the United States for adults with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. Kura also evaluates ziftomenib in other leukemia settings and in combination with imatinib for gastrointestinal stromal tumors. Its other programs include KO-7246 for diabetes and cardiometabolic disorders, additional menin inhibitors for solid tumors, and darlifarnib for solid tumors including renal cell, lung, colorectal and pancreatic cancers. Kura makes money from U.S. KOMZIFTI sales, which it records, and shares commercialization profits and losses equally with Kyowa Kirin. Kyowa Kirin handles commercialization and sales outside the United States. Kura is headquartered in San Diego, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $KURA in the last 30 days.
See all $KURA insider activity →Kura Oncology (KURA) reported Q3 net loss of $70.2M, down 5% YoY. The company presented plans for ziftomenib, including combination studies and frontline trials, with top-line results expected in 2028. Kura also announced plans for darlifarnib studies and a financing agreement with Oberland Capital. Cash reserves stood at $492M, with guidance for 2026-2028 collaboration revenue.
Kura Oncology, Inc. (KURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kura Oncology Reports THIRD Quarter 2026 Financial Results AND CORPORATE UPDATE – KOMZIFTI ® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% – – KOMZIFTI maintained majority sh
Kura Oncology (KURA) and Kyowa Kirin had eight ziftomenib abstracts accepted for ASH 2026, including four oral presentations. Kura will report Q3 2026 results on Nov. 10, with expected loss of $0.82 per share and $22.9M revenue. The company granted new hires options for 55,500 shares at $9.79.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning KURA (Kura Oncology, Inc.). Coverage has been balanced: 2 bullish, 2 neutral, and 2 bearish.
Recent KURA coverage spans financial news, earnings and technology.
Guidance modestly raised and new financing may support cash runway, but a net loss and limited near-term data keep upside limited.
Positive earnings beat and strong financing suggest upside.
Upcoming earnings and positive conference abstracts may drive short-term volatility.
Analyst downgrade likely pressures the stock lower.
New early‑stage data on ziftomenib combos could boost investor optimism for the AML drug and lift KURA stock.
AlphAI scores every news story that mentions KURA with an AI model for sentiment and relevance, and aggregates insider trades from Kura Oncology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kura Oncology (KURA) reported Q3 net loss of $70.2M, down 5% YoY. The company presented plans for ziftomenib, including combination studies and frontline trials, with top-line results expected in 2028. Kura also announced plans for darlifarnib studies and a financing agreement with Oberland Capital. Cash reserves stood at $492M, with guidance for 2026-2028 collaboration revenue.
Kura Oncology, Inc. (KURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kura Oncology Reports THIRD Quarter 2026 Financial Results AND CORPORATE UPDATE – KOMZIFTI ® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% – – KOMZIFTI maintained majority sh
Kura Oncology (KURA) and Kyowa Kirin had eight ziftomenib abstracts accepted for ASH 2026, including four oral presentations. Kura will report Q3 2026 results on Nov. 10, with expected loss of $0.82 per share and $22.9M revenue. The company granted new hires options for 55,500 shares at $9.79.
StoneX kept its Buy rating on Kura Sushi USA but reduced its price target from $85 to $55, a 35.3% cut. This implies a 48.4% upside from the Nov 5 close of $37.07.
Kura Oncology (KURA) and Kyowa Kirin (4151) will present data on ziftomenib, their leukemia drug, at the 2026 ASH Annual Meeting. Key presentations include combination results with quizartinib and gilteritinib, longer-term data with venetoclax and azacitidine, and exploratory analysis in additional AML subtypes. The companies aim to establish ziftomenib as a preferred menin inhibitor for combination treatments. An investor webcast is scheduled for December 15, 2026.
DA Davidson kept a Buy rating on Kura Sushi USA with a $55 price target, suggesting a 44% upside from the Oct 14 close. The firm expects 20% unit growth by FY27 and improved margins from efficiency initiatives, including robotic dishwashers.
Cantor Fitzgerald maintained an Overweight rating on Kura Oncology (KURA) after a webinar with Caspian Therapeutics, its spin-out. The stock is down 8% this week. Analysts revised earnings upwards, with price targets ranging from $15 to $30. KURA is developing KO-7246 for diabetes, with proof-of-concept data expected by 2028-2029. The CEO recently bought $1.24M in company stock.
Citizens reiterated a Market Outperform rating and $24.00 price target for Kura Oncology (NASDAQ:KURA), citing potential upside of over 140% from the current stock price of $9.83. The firm's view is based on discounted EPS and revenue multiple analysis, and recent preclinical data for KO-7246. Kura reported strong Q2 2026 results, with UBS and JPMorgan also issuing positive ratings and price targets. The company's CEO made significant insider stock purchases, reflecting confidence in its future.
Caspian Therapeutics and Kura Oncology (KURA) will discuss the development strategy for KO-7246, an oral menin inhibitor for diabetes, in a webcast. Preclinical findings showed improved glucose control and beta cell expansion in animal models. Caspian plans to conduct a Phase 1 clinical trial to assess safety and insulin production. Kura owns half of Caspian and retains research collaboration rights.
Kura Oncology (KURA) will host a webcast on Oct. 13 with Caspian Therapeutics to discuss Caspian's formation and preclinical diabetes data for KO-7246, a menin inhibitor in development for metabolic applications. The webcast follows data presented at EASD.
